12/28/2020 7:32:14 AM
Navidea Appoints Malcolm Witter To Its Board
8/10/2020 9:22:17 AM
Jubilant And Navidea Sign Binding MoU For Commercialization Partnership
8/10/2020 7:45:45 AM
Navidea Signs Binding MOU With Jubilant Draximage
6/3/2020 7:55:25 AM
Navidea To Present Results From First Interim Analysis Of NAV3-31 Phase 2b Clinical Study
5/11/2020 7:34:07 AM
Navidea Biopharma Regains Commercialization And Distributions Rights In Europe For LYMPHOSEEK
4/22/2020 7:41:49 AM
Navidea Biopharma Says On Track To Deliver Interim Data From Arm 3 Of Its Phase 2b Clinical Trial For RA
3/31/2020 7:38:36 AM
Navidea Signs LoIt With WorldCare Clinical To Partner On Navidea's Rheumatoid Arthritis Clinical Imaging Workflow
3/20/2020 7:08:39 AM
Navidea Reports Issuance Of Patent Extension For
Lymphoseek
3/11/2020 4:10:00 PM
Navidea Biopharmaceuticals Q4 Loss/share $0.15 Vs. Loss $0.33 Year Ago
2/14/2020 11:59:44 AM
Navidea Biopharmaceuticals Regains Compliance With NYSE American Continued Listing Standards
2/14/2020 7:31:21 AM
Navidea Says $4.2 Mln Sale Of Ohio Court Judgment & $3.4 Mln Equity Raise Representing $7.6 Mln In Addl Funding
11/7/2019 7:34:56 AM
Navidea Biopharma Announces Preclinical Therapeutic Research Collaboration With IMV
8/27/2019 7:33:05 AM
Navidea Reports Receipt Of Notice Of Award From NIH
6/24/2019 7:57:19 AM
Navidea Biopharmaceuticals Announces Recognition Of Phase 1/2 Study Results
6/13/2019 11:26:59 PM
Navidea Biopharma Prices Underwritten Public Offering Of 8 Mln Shares At $0.75/shr
4/8/2019 7:40:31 AM
Navidea Receives FDA Feedback On Rheumatoid Arthritis Clinical Trial Design